Xarelto on prevention of stroke and non-Central Nervous Systemic embolism in Renally impaired Korean patients with Non-valvular Atrial fibrillation (XARENAL)
The purpose of the study is to evaluate the safety and effectiveness of Xarelto in renally impaired patients
with NVAF under routine practice conditions.
The information collected in the XARENAL study will help to understand how renally impared patients with
NVAF are treated in the real-world setting and what the outcome for the patients is under those conditions.
- Female and male patients ≥ 19 years of age - Diagnosis of NVAF - Patients for whom the decision to initiate treatment with rivaroxaban has already been made as per physician’s routine treatment practice - Previous documented creatinine clearance rate of 15-49mL/min within 6 months before enrollment - Written informed consent of the patient
- Contraindications for rivaroxaban according to the current Korean market authorization and Summary of Product Characteristics (SmPC). - Patients participating in an investigational program with interventions outside of routine clinical practice. - Planned treatment with other anticoagulants. - Expected renal-replacement therapy within the next 3 months
Many locations, South Korea
E-mail: [email protected]
Phone: (+)1-888-84 22937
Xarelto® on prevention of stroke and non-Central Nervous Systemic (CNS) embolism in Renally impaired Korean patients with Non-valvular Atrial fibrillation (NVAF)